Compare · BSX vs XAGE
BSX vs XAGE
Side-by-side comparison of Boston Scientific Corporation (BSX) and Longevity Health Holdings Inc. (XAGE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and XAGE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX carries a market cap of $60.90B.
- XAGE has been more active in the news (3 items in the past 4 weeks vs 2 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 0 for XAGE).
- Company
- Boston Scientific Corporation
- Longevity Health Holdings Inc.
- Price
- $62.06-5.52%
- $2.32-15.02%
- Market cap
- $60.90B
- -
- 1M return
- -11.05%
- -
- 1Y return
- -39.23%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 2
- 3
- Recent ratings
- 25
- 0
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Boston Scientific announces results for first quarter 2026
- SEC Form EFFECT filed by Boston Scientific Corporation
- SEC Form 424B3 filed by Boston Scientific Corporation
- Boston Scientific downgraded by Raymond James with a new price target
- Boston Scientific announces conference call discussing first quarter 2026 results
- Amendment: SEC Form S-4/A filed by Boston Scientific Corporation
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
- HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism
Latest XAGE
- SEC Form SCHEDULE 13D filed by Longevity Health Holdings Inc.
- SEC Form 4 filed by Ajjarapu J. Ram
- SEC Form 3 filed by new insider Ajjarapu J. Ram
- SEC Form 424B3 filed by Longevity Health Holdings Inc.
- SEC Form 10-K filed by Longevity Health Holdings Inc.
- Longevity Health Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Longevity Health Holdings Closes Strategic Investment and Appoints Ram Ajjarapu as Chairman and CEO to Drive Acquisition-Focused Growth
- SEC Form 424B3 filed by Longevity Health Holdings Inc.
- Longevity Health Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
- SEC Form 25-NSE filed by Longevity Health Holdings Inc.